about
New Antituberculosis Drugs: From Clinical Trial to Programmatic UseTuberculosis case finding based on symptom screening among immigrants, refugees and asylum seekers in RomeMultidrug-resistant tuberculosis in Europe, 2010-2011Active Tuberculosis Case Finding Interventions Among Immigrants, Refugees and Asylum Seekers in Italy.Improved detection of human influenza A and B viruses in respiratory tract specimens by hemi-nested PCR.Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure.Modulation of CD4 and CD8 response to QuantiFERON-TB Plus in patients with active tuberculosis and latent tuberculosis infection followed over time during treatment.Use of several immunological markers to model the probability of active tuberculosis.Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis.The diabetes-tuberculosis co-epidemic: the role of international migration.Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.IFNγ/TNFα specific-cells and effector memory phenotype associate with active tuberculosis.Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy.Treatment outcomes of MDR-TB and HIV co-infection in Europe.Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.ERS/ECDC Statement: European Union Standards for Tuberculosis Care - 2017 update.Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries.Treatment Outcomes in Multidrug-Resistant Tuberculosis.Phylogenetic analysis of human coronavirus NL63 circulating in ItalyBurden and Characteristics of the Comorbidity Tuberculosis-Diabetes in Europe: TBnet Prevalence Survey and Case-Control StudyWorld Tuberculosis Day March 24th 2019 Theme: "It's TIME" - International Journal of Infectious Diseases Tuberculosis Theme SeriesPutting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy[An integrated model for the evaluation and risk management of tuberculosis infection and active tuberculosis in homeless people in the city of Rome (Italy)]Multidrug-Resistant Tuberculosis In A Referral Center In Rome: 2011- 2016Tuberculin skin test - Outdated or still useful for Latent TB infection screening?
P50
Q26741138-B70312EC-7B91-458F-96DF-D7071ECE30C2Q34992915-9495BF25-BF1C-4FCD-A064-1DCA85FFEE29Q35130346-3FC726F3-0CAF-4DE3-A3EA-F7096B204835Q37054030-B3AA4E8F-D790-4740-8B21-5CB19C73B1BEQ38305340-688BE26E-925E-4B0D-9E21-F9AF22D5EC53Q38915347-C4A80408-2CB0-4630-86D8-777B22511BFBQ39524363-16628176-FA3B-4B8E-849E-3D48F7B9E74FQ39524371-BC63548D-F4F0-4A4C-B159-5CB5C4F7E6B1Q40286070-8CF12C78-88C4-4B7A-A017-F3A66F793892Q40388240-89FDA498-E457-485E-A252-64ADDC52CA3DQ40608763-FE1554E9-DD7C-4825-8E2F-A9816D578B6EQ40647796-C0E3FD40-910B-472B-BAA1-BD1C2EB5E33FQ40683749-93615833-9911-4588-9F43-8D5D49195BFAQ40891947-E550FE14-473F-4B00-B48E-B52652DD92A2Q42272434-95A90253-CE48-408A-BA6B-A0A174148A3FQ47130912-AA70D79B-46C0-4002-B7BB-F27C0BCA62ABQ47868204-EF1B3BE1-935C-42AD-90D3-C7BCAB1E95DCQ47941932-D642E341-E69F-4832-A0B4-DCCD749BD149Q48259688-B7EEF327-4768-40E7-BD35-A468B5CE2288Q51544855-3B563C24-3147-4C9D-8DF2-B1DE3479418AQ52573425-1F9EA228-F36E-4AC0-9278-F405A6D0F998Q53704318-5603D485-7223-47DF-BC2E-6548F682CE08Q53769778-8798018E-31B4-4906-93D1-A7844DB3EAC1Q56790267-2A4AAF46-28C3-433E-B4DD-486C2BE9545AQ61443600-17E54B57-4967-41E3-9665-5F27B5852164Q62486698-E0DD0E99-DDE8-4688-AD44-86BCC95A66B6Q63880802-129D18A3-FFBD-4BB7-9004-4974D04FA01BQ79790468-1F8ABA8E-0CD3-490B-A89B-BD6DA3FDDEF3Q91153159-CF0633BF-1712-43AC-91E8-E5AEEF7C3B15Q91433643-8D3A8E67-A4FC-4DD6-B5C8-76FFCE079BF6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gina Gualano
@ast
Gina Gualano
@en
Gina Gualano
@es
Gina Gualano
@nl
Gina Gualano
@sl
type
label
Gina Gualano
@ast
Gina Gualano
@en
Gina Gualano
@es
Gina Gualano
@nl
Gina Gualano
@sl
prefLabel
Gina Gualano
@ast
Gina Gualano
@en
Gina Gualano
@es
Gina Gualano
@nl
Gina Gualano
@sl
P106
P31
P496
0000-0001-6149-0005